OKYO Pharma Limited Sponsored ADR OKYO
1.38
0.00
0.00%
as of 25 Sep
- Market cap
- $72.4M
- P/E
- 0.0×
Follow OKYO
Insider Buys
alert about insiders buying in the last 12 month
| Mar '19 | Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
1.78 | 0.80 | 4.09 | 3.17 | 0.72 | 0.21 | 0.40 | 2.43 |
Net Debt/EBITDA |
0.13 | 0.13 | 2.02 | 0.43 | 0.14 | 0.05 | 0.22 | 2.42 |
Debt/Assets |
0.00% | 5.29% | 1.39% | 0.00% | 42.57% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (0.23) | 0.02 | 0.00 | (1.08) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.41 | 0.88 | 0.48 | 1.01 | 0.58 | 0.56 | 0.38 | 0.66 |
Capex/Depreciation |
0.00 | 0.00 | (4.60) | (0.74) | (1.55) | 0.00 | (0.46) | (3.39) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | (1,600.62%) | (129.50%) | (131.39%) | (2,968.40%) | 424.20% | 82.36% | (263.79%) | |
| 0.00% | (227.14%) | (87.22%) | (95.35%) | (279.27%) | (498.89%) | (180.37%) | (72.60%) | |
ROIC |
0.00% | 0.00% | 0.00% | (1,575.19%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(1,482.57%) | 1,357.57% | (63.45%) | (184.26%) | 646.36% | 286.17% | 84.80% | (72.55%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
0.00 | 0.00 | (0.31) | (0.36) | (0.35) | (0.32) | (0.05) | (0.16) |
Cash per Share |
0.00 | 0.00 | 1.34 | 0.18 | 0.18 | 0.03 | 0.04 | 0.55 |
Shareholders Equity per Share |
0.00 | 0.00 | 1.03 | 0.20 | (0.09) | (0.20) | (0.14) | 0.33 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.00 | 1.03 | 0.20 | (0.09) | (0.20) | (0.14) | 0.33 |
Free Cash Flow |
(2.00) | (1.35) | (1.61) | (5.47) | (7.70) | (9.49) | (1.81) | (5.94) |
Working Capital |
0.33 | (0.14) | 5.28 | 2.94 | (2.06) | (5.88) | (5.55) | 12.33 |
Capital Expenditures |
0.00 | — | (0.01) | 0.00 | (0.01) | — | 0.00 | (0.01) |
Net Current Asset Value |
0.33 | (0.17) | 5.21 | 2.94 | (2.06) | (5.88) | (5.55) | 12.33 |
| Other line items | ||||||||
Quick Ratio |
1.73 | 0.79 | 4.09 | 3.17 | 0.72 | 0.21 | 0.40 | 2.43 |
Depreciation/Fixed assets |
0.18 | 0.20 | 0.25 | 0.44 | 0.53 | 1.15 | 1.30 | 0.29 |
Cash ROIC |
(208.72%) | (1,088.75%) | (13.05%) | (96.91%) | (183.07%) | 187.89% | 45.45% | (18.05%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
0.00 | 0.00 | (0.31) | (0.36) | (0.35) | (0.32) | (0.05) | (0.16) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.22 | 0.21 | 0.85 | 1.37 | 0.93 | 1.41 | 1.25 |
Average Payables |
— | — | — | 1.49 | 2.78 | 5.66 | 7.71 | 8.50 |
Average Assets |
— | 0.68 | 3.85 | 5.70 | 4.75 | 3.37 | 2.61 | 12.33 |
Average Common Equity |
— | 0.10 | 2.59 | 4.13 | 0.45 | (3.97) | (5.71) | 3.39 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates